Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4)

 Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4)

Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4)

Shots:

  • Immunocore to receive $100M upfront plus milestone payment and has an option to license IMC-C103C or grant its full rights to Genentech. If not exercised option to license, Immunocore will receive milestones and royalties
  • Immunocore will conduct clinical trial to evaluate IMC-C103C as a monothx or in combination with Tecentriq (atezolizumab), which will be initiated in H1’19
  • IMC-C103C is a mAb, is being developed for targeting tumors expressing protein MAGE-A4 (Melanoma-Associated Antigen A4)

Click here to read full press release/ article | Ref: Immunocore| Image: Center for Health Journalism

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post